مواقع التدريسيينجامعة الكوفة
Hussein Abdulkadhim Abdulhussein Aljanabi
Assistant Professor

Hussein Abdulkadhim Abdulhussein Aljanabi

0Publications
0Interests
0News

About

Graduated from the College of Medicine in 1997, I worked in the residency in Kadhimiya Hospital and then obtained a master's degree in medicine and therapeutics from the same college in 2001 and a Ph.D. Department of medicines from 2005 to 2009 and then transferred my angel to the Faculty of Medicine Kufa
Adopted the industrial research project to contribute to solving some of the health challenges and invite researchers to train on this scientific field, which suffers from neglect and ignore has achieved in this field several patents to become a research value practical and easy access to people that are in dire need of new therapeutic solutions after busy Most fields of treatment with commercial competition
It also adopted the integrated knowledge project, which ensures the balance of specialized sciences with holistic sciences that raise the efficiency of individual knowledge and professional performance to strive for a conscious and balanced life.
I adopt the systematic teaching method, a methodology that makes the information parts in a system that is easy to identify the recipient and develops the basis of detailed knowledge, making it more established and closer to the application

Research Interests

1

Publications

4
Received: 12/09/2019

The Potency of a Combined Diclofenac-Ampiclox against Streptococcus Pyogen Isolated from Patients with Pharyngitis: A pilot study

AuthorsRana Talib Al-Nafakh, Hussein Abdulkadhim 2 , and Naser A Naser
JournalAnnals of Tropical Medicine & Public Health
Abstract

Abstract Background: Pharyngitis, scarlet fever, and rheumatic fever are of the major infectious problems caused by Streptococcus pyogen. Emergence of antibiotic- resistant strains makes such infection, its rheumatic valvular disease, and glomerulonephritis complications a serious clinical challenge especially in children. Aims and objectives: In a maneuver of overcoming S. pyogen resistance and improve its response to antibiotic, a no steroidal anti-inflammatory drug NSAID is repurposed as antimicrobial against S. pyogen. In intention to be combined with the classical antibiotic recommended by WHO guideline of care. The combination was assessed for its MIC and combination index against S. pyogen. Materials and Methods: A multidrug-resistant strain of S. pyogen was isolated from patients, suffering pharyngitis. The most serious isolate was cultivated for MIC determination of ampiclox￾diclofenac combination in comparison with each alone to determine the combination index. Results and conclusions: There was a significant synergism between ampiclox-diclofenac (index ˂ 1) at P= 0.012 and Z score= 2.3 further confirmation of MIC folds of dilutions are to be assessed to obtain reasonable evidence. Recommendations: We recommended to further confirm the antistreptococcal effect of the combined ampiclox-diclofenac on more dilutions of MIC assay and to analyze data of this combination in patients with S. pyogen pharyngitis.

????

Assessment of Anticancer Effects of the Investigational Agent MEX2R as K-RAS Oncogene Blocker in Human Colorectal Cancer Cells Model SW480 Cell Line

AuthorsZahraa Fathi Sharba, Hussein Abdul Kadim A1 , Kifah Jabbar Alyaqubi2 and Hamid Naji Obied3
JournalInternational Journal of Medical Research & Health Sciences, 2018, 7(12): 24-30
Abstract

ABSTRACT Objective: To survey K-RAS blocker of choice among a group of inhibitors with characterizing their safety profile in colorectal carcinoma. An experimental model of continuous SW480 cell line and Vero cell line was applied, in vitro assessment by using tissue culture as a standard technique for checking the cytotoxicity of many compounds and in development of new drugs. Materials and methods: This study tested the cytotoxicity assay of MEX2R and chemotherapy (methotrexate) as comparative agents in the mechanism of action with the tested drug by Crystal Violet assay (CV). After exposure both SW480 cell line and Vero cell line were treated first to different concentrations of MEX2R compound (15.625, 31.25, 62.5, 125, 250 and 500) μg/ml for 36 hours and secondly to different concentrations of methotrexate (15.625, 31.25, 62.5, 125, 250 and 500) μg/ml for 36 hours. Results: The results showed that the investigational agent MEX2R exhibits highly significant cytotoxic effects (p ≤ 0.05) in SW480 colorectal cancer cells when compared with control (untreated cells), and less cytotoxic influences on normal Vero cell line in a dose￾dependent manner. The tested drugs showed anticancer activity with half maximal growth inhibitory concentrations (IC50) for MEX2R 65.738 μg/ml which was more potent than antitumor drugs methotrexate (MTX) that has cell cycle arrest activity like investigational agent’s action, IC50 of MTX was about 93.574 μg/ml. The selectivity index of MEX2R compound (3.252) was higher than the selectivity index of MTX (2.65). Conclusion: From the overall results, MEX2R has highly significant cytotoxic effects on SW480 colorectal cancer cell line when compared with MTX, also MEX2R agent possessed safe profiles in Vero cell line as normal cells in comparison with standard chemotherapy MTX

2018

CYTOTOXIC ACTIVITY OF COMPOUNDED ANTHRACYCLINE AGAINST RHABDOMYOSARCOMA CANCER CELL LINE

AuthorsMerza Hemza Homady, Hussein Abdul Kadhim2 , Khalida K. Abbas Al-Kelaby3 , Dhifaf Zeki Aziz1 * and Naser Jawad Kadhim1
JournalPlant Archives Vol. 18
Abstract

High selectivity of Cytotoxic Activity of Compounded Anthracycline against Rhabdomyosarcoma Cancer Cell Line that effect of DMT between cancer cell and normal cell line increase the prospects that this compound could serve as leads for novel anticancer drugs and hence may be potential candidates for use in human cancer therapy, however, further investigations will be required in this regard to validate this hypothesis. Key words : Cytotoxic activity, anthracycline, human cancer therapy, anticancer drugs.

2017

ASSESSMENT OF COMPOUNDED DOXORUBICIN IN CARDIAC TISSUE OF EXPERIMENTAL ANIMALS

AuthorsDhifaf Zeki Aziz, Merza Hemza Homady1 , Hussein Abdul Kadim2 , Khalida K. Abbas Al-Kelaby3
JournalPak.J. Biotechnol. Vol. 14 (4) 811-816 (2017)
Abstract

Doxorubicin is one of the most important anticancer agents, but its clinical uses are limited due to cardiotoxicity, the present study evaluated the effects of new derivatives of doxorubicin on cardiac tissue by the measurement of serum cardiac troponin I (cTnI) and CK-BM assays as biomarkers as well as heart tissue after 3 weeks of treatment in albino mice. The results indicated that TnI was significantly elevated (P≤ 0.05) in all studied groups when compared with the control, also serum CK-MB was significantly elevated (P≤ 0.05) in all studied groups except that treated with a new compound when compared with the control group. The histopathological study of heart tissue revealed that the treatment with this compound showed less changes in heart tissue.

News & Announcements

2
Announcements 2019-11-13

Update in treatments of serious diseases for 2019

The new treatments of serious illnesses like cancer, diabetes mellitus and genetic diseases

News 2019-11-11

The department of pharmacology and therapeutics will conduct series of workshops about the scientific research process

Those workshops encompass how to design a proper research concept, how to ensure research quality in lab technique, what are the principles of writing a a scientific paper

View details